Kura Oncology, Inc.
KURA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.50 | -2.80 | -2.01 | -0.43 |
| FCF Yield | 17.84% | -11.87% | -13.31% | -11.38% |
| EV / EBITDA | -3.20 | -6.26 | -5.88 | -6.52 |
| Quality | ||||
| ROIC | -28.50% | -39.94% | -32.24% | -25.43% |
| Gross Margin | 98.43% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.77 | 0.82 | 0.81 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 207.08% | -12.92% | -4.72% | -46.80% |
| Safety | ||||
| Net Debt / EBITDA | 1.23 | 0.12 | 0.28 | 0.65 |
| Interest Coverage | -119.33 | -107.04 | -610.76 | -318.40 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -590.97 | -988.81 | -737.21 | -2,116.74 |